<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653649</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-CAR-2019-30</org_study_id>
    <nct_id>NCT04653649</nct_id>
  </id_info>
  <brief_title>CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.</brief_title>
  <official_title>Immunotherapy With Autologous CAR30 T Cells for Patients With Classic Hodgkin Lymphoma and Non-Hodgkin T-cell Lymphoma With CD30 Expression.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Josep Carreras Leukaemia Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HSP-CAR30 is a cell suspension of genetically modified T-cells to express a second generation&#xD;
      (4-1BBz) chimeric antigen receptor (CAR) directed against CD30.&#xD;
&#xD;
      This is a phase I/IIa, interventional, single arm, open label, treatment study to evaluate&#xD;
      the safety, tolerability and efficacy of HSP-CAR30 in patients with relapsed/refractory&#xD;
      Hodgkin lymphoma and relapsed/refractory T-cell lymphoma expressing CD30.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Experimental: HSP-CAR30 (anti-CD30 CAR T cells)&#xD;
Dose escalation phase:&#xD;
Phase I:&#xD;
Ten patients will be treated with HSP-CAR30 (anti-CD30 CAR T-cells) with an escalation approach to define maximum tolerated dose (MTD) from 3 x 106/kg to 10 x 106/kg.&#xD;
Phase IIa:&#xD;
Twenty patients will be treated with HSP-CAR30 at MTD to evaluate efficacy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess safety and toxicity of the administration of autologous anti-CD30 CAR T-cells</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with cytokine release syndrome and/or ICANs grade 1-4 according to ASBMT Consensus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To establish the maximum tolerated dose (MTD; defined as the dose that induces maximum limiting toxicity) of autologous anti-CD30 CAR T-cells in patients with refractory or relapsed classic Hodgkin or CD30 + T NHL.</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients receiving maximum dose (1 x 10e7/kg CART+ cells) without DLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To analyze the rate of complete responses at 3 months after the procedure</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hodgkin Lymphoma, Adult</condition>
  <condition>T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>HSP-CAR30 (anti-CD30 CAR T cells)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I:&#xD;
Ten patients will be treated with HSP-CAR30 (anti-CD30 CAR T-cells) with an escalation approach to define maximum tolerated dose (MTD) from 3 x 106/kg to 10 x 106/kg.&#xD;
Phase IIa:&#xD;
Twenty patients will be treated with HSP-CAR30 at MTD to evaluate efficacy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HSP-CAR30</intervention_name>
    <description>Anti-CD30 CAR T-cells</description>
    <arm_group_label>HSP-CAR30 (anti-CD30 CAR T cells)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Classic Hodgkin lymphoma:&#xD;
&#xD;
               -  Relapsed patients after autologous hematopoietic stem cell transplantation who&#xD;
                  have already received Brentuximab-Vedotin and anti-PDL1 antibodies, OR&#xD;
&#xD;
               -  Primarily refractory patients who do not reach CR after rescue, including&#xD;
                  Brentuximab-Vedotin and anti-PDL1 antibodies.&#xD;
&#xD;
          -  Anaplastic large T-cell lymphoma (ALK+/ALK-) and peripheral T-cell lymphoma&#xD;
             (NOS/Angioimmunoblastic):&#xD;
&#xD;
               -  &gt;90% of tumor cells expressing CD30 determined by immunohistochemistry, AND&#xD;
&#xD;
               -  Relapsed patients after autologous hematopoietic stem cell transplantation, OR&#xD;
&#xD;
               -  Primarily refractory patients (after first line, including anthracycline) who do&#xD;
                  not achieve CR after rescue.&#xD;
&#xD;
               -  All patients must sign an informed consent before starting any procedure.&#xD;
&#xD;
               -  All patients must have measurable disease (detected by PET-CT) at the time of&#xD;
                  inclusion.&#xD;
&#xD;
               -  Performance status: ECOG 0-1&#xD;
&#xD;
               -  FEV1&gt; 39%; DLCO and FVC&gt; 39% of NV.&#xD;
&#xD;
               -  No significant ventricular dysfunction: EF &gt;45%.&#xD;
&#xD;
               -  Total bilirubin and transaminases &lt;3 times the maximum normal value, unless&#xD;
                  attributable to lymphoma.&#xD;
&#xD;
               -  Creatinine &lt;2 times the normal maximum value and clearance&gt; 40 mL/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Performance status: ECOG 2-4&#xD;
&#xD;
          -  Prior allogeneic haematopoietic stem cell transplant.&#xD;
&#xD;
          -  Active hepatitis B, C or HIV infection&#xD;
&#xD;
          -  Active bacterial, fungal, or viral infection.&#xD;
&#xD;
          -  Evidence of CNS involvement by lymphoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Briones, MD, PhD</last_name>
      <phone>+34935565649</phone>
      <email>jbriones@santpau.cat</email>
    </contact>
    <contact_backup>
      <last_name>Ana Carolina Caballero, MD</last_name>
      <phone>+34935565649</phone>
      <email>acaballero@santpau.cat</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

